Amneal Pharmaceuticals (NASDAQ:AMRX) Updates FY 2025 Earnings Guidance

Amneal Pharmaceuticals (NASDAQ:AMRX) updated its FY 2025 earnings guidance on Tuesday. The company provided earnings per share guidance of 0.750-0.800 for the period. The company issued revenue guidance of $3.0 billion-$3.1 billion.

Amneal Pharmaceuticals Trading Down 0.1%

Amneal Pharmaceuticals stock opened at $12.97 on Wednesday. The company has a market cap of $4.08 billion, a price-to-earnings ratio of 648.82 and a beta of 1.34. Amneal Pharmaceuticals has a 12 month low of $6.68 and a 12 month high of $13.48. The business’s 50 day simple moving average is $12.32 and its 200 day simple moving average is $10.39.

Amneal Pharmaceuticals (NASDAQ:AMRX) last posted its earnings results on Thursday, October 30th. The company reported $0.17 earnings per share for the quarter, topping analysts’ consensus estimates of $0.12 by $0.05. Amneal Pharmaceuticals had a net margin of 0.20% and a negative return on equity of 185.60%. The business had revenue of $784.51 million for the quarter. Amneal Pharmaceuticals has set its FY 2025 guidance at 0.750-0.80 EPS. As a group, equities research analysts forecast that Amneal Pharmaceuticals will post 0.53 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on AMRX. JPMorgan Chase & Co. increased their target price on Amneal Pharmaceuticals from $12.00 to $14.00 and gave the company an “overweight” rating in a research report on Tuesday, September 16th. Piper Sandler reiterated an “overweight” rating and issued a $13.00 target price (up previously from $11.00) on shares of Amneal Pharmaceuticals in a research note on Friday, October 31st. Weiss Ratings reiterated a “hold (c)” rating on shares of Amneal Pharmaceuticals in a report on Wednesday, October 8th. Truist Financial set a $15.00 target price on shares of Amneal Pharmaceuticals in a report on Wednesday, January 7th. Finally, Barclays began coverage on Amneal Pharmaceuticals in a research report on Monday, December 8th. They issued an “overweight” rating and a $15.00 price target for the company. Four analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, Amneal Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $13.80.

Insider Buying and Selling

In related news, EVP Nikita Shah sold 131,856 shares of the company’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $11.92, for a total value of $1,571,723.52. Following the transaction, the executive vice president directly owned 146,403 shares in the company, valued at approximately $1,745,123.76. This represents a 47.39% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Ted C. Nark sold 50,000 shares of the firm’s stock in a transaction on Monday, November 17th. The stock was sold at an average price of $11.72, for a total value of $586,000.00. Following the transaction, the director owned 291,029 shares of the company’s stock, valued at approximately $3,410,859.88. This represents a 14.66% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 231,856 shares of company stock worth $2,743,724 over the last ninety days. Corporate insiders own 17.45% of the company’s stock.

Hedge Funds Weigh In On Amneal Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Comerica Bank grew its stake in Amneal Pharmaceuticals by 186.7% during the 3rd quarter. Comerica Bank now owns 3,005 shares of the company’s stock valued at $30,000 after purchasing an additional 1,957 shares in the last quarter. Focus Partners Wealth bought a new position in shares of Amneal Pharmaceuticals during the third quarter worth about $42,000. Advisory Services Network LLC acquired a new stake in shares of Amneal Pharmaceuticals in the third quarter valued at approximately $50,000. Bellevue Group AG bought a new stake in Amneal Pharmaceuticals during the 3rd quarter valued at $79,000. Finally, Mercer Global Advisors Inc. ADV acquired a new stake in Amneal Pharmaceuticals in the third quarter worth about $105,000. 31.82% of the stock is owned by institutional investors and hedge funds.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.